Skip to main content

CCTG Connection



Published:
Category: Publications
CCTG publications for CO20, MAC4/MAC5, MEC3 recently added to the group database. Read More



Published:
Category: Group updates

The main purpose of this job is to provide electronic clinical database management from collection and entry to statistical analysis and reporting of data.

Read More

Published:
Category: Group updates

The Panel on Research Ethics and the Secretariat on Responsible Conduct of Research are pleased to announce the release of TCPS 2: CORE-2022.

Read More

Published:
Category: Group updates

The Frances A Shepherd Award is awarded to investigators or post-graduate trainees, traveling to present CCTG related work at major international meetings where the material has been accepted for presentation. Each award will be approximately $1000 and offered twice a year. Applicants who have had their research accepted for oral or poster presentation at an international scientific meeting and have not received another award to support their travel are eligible to apply.

Read More

Published:
Category: Group updates

We are getting closer to the 2022 Virtual CCTG Annual Spring Meeting of Participants which will be held from April 28 - May 01, 2022!

Read More

Published:
Category: Group updates

Louise joined the CCTG Patient Representative Committee last year and is supporting the Melanoma & Quality of Life Committees. She is a married mother of five and Nana to 11 who enjoys spending time with her family, gardening and reading. Louise’s background is in Education and has participated as a Patient Partner in many groups and projects on both a National and Provincial level.

"I hope to improve the Patient experience and to encourage cancer patients to be involved in clinical trials and help foster change to improve the future of treatments," says Louise

Read More

Published:
Category: Publications
Multiple publications newly added to the group database: CO15, MAC14, MA37, General Review Publication Read More

Published:
Category: Trials
The REC2 ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma and the MYX1 trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies have been permanently closed. Read More